Novartis Consumer Health Sales Force To Detail Barrier’s Vusion Ointment
This article was originally published in The Pink Sheet Daily
Executive Summary
Barrier also moving forward with Phase IV commitments, exec tells “The Pink Sheet” DAILY.
You may also be interested in...
Barrier Seeks Development Partner For Its Liarozole Treatment In Lamellar Ichthyosis
Phase II/III trial fails to meet primary endpoint; FDA and EMEA want more clinical trials, firm tells “The Pink Sheet” DAILY.
Barrier Seeks Development Partner For Its Liarozole Treatment In Lamellar Ichthyosis
Phase II/III trial fails to meet primary endpoint; FDA and EMEA want more clinical trials, firm tells “The Pink Sheet” DAILY.
Vusion Breaks “Not Approvable” Barrier With Dermatitis NDA
Barrier Therapeutics receives FDA approval for the antifungal ointment after submitting a complete response to a May 2005 “not-approvable” letter.